

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.



For immediate release

Curetis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels

Holzgerlingen, Germany, October 14, 2015 -- Curetis AG (“**Curetis**”), a developer of next-level molecular diagnostic solutions, today announces its intention to launch an Initial Public Offering (the “**IPO**” or the “**Offering**”) of new ordinary shares in the capital of a newly incorporated Dutch holding company – Curetis N.V.¹ – and the listing of all ordinary shares on Euronext in Amsterdam and Euronext in Brussels.

Company Highlights

Commercial-stage molecular diagnostics for the simple, accurate and rapid detection of infectious diseases and antibiotic resistance in severely ill, hospitalized patients at the point of need.

- With its Unyvero Platform, Curetis has developed a walk-away solution that detects a broad range of different microorganisms and antibiotic resistance markers in a single test from a wide variety of native sample materials within four to five hours. In contrast, the diagnosis of infectious diseases in a hospital setting today is still largely carried out through traditional microbiology culture based tests, a labor-intensive and time-consuming process typically delivering results only after 24 to 72 hours or even weeks.
- The Unyvero Platform allows clinicians to make early adjustments to a more specific treatment of the patient, saving significant time and cost, in particular by reducing the time of the patient's hospital stay. Moreover, informed therapy decisions may prevent or decrease the risk of antibiotic resistance development, a major challenge in healthcare worldwide.

Versatile, robust CE-marked Unyvero Platform

- The CE-IVD marked Unyvero Platform is designed as a robust, infrastructure-independent, near-patient solution that can be operated automatically with minimal hands-on time and by non-laboratory staff. It has been validated in over 30 completed clinical studies and endorsed by key opinion leaders.
- It consists of instruments (L4 Lysator, C8 Cockpit, and A50 Analyzer), proprietary software, and disposable Application Cartridges specifically designed for various indication areas.
- It deals with a large variety of sample types and covers more microorganisms and resistance markers than competing platforms.

¹ Curetis N.V. is currently still named Curetis B.V. and will be converted into a Dutch public company with limited liability (N.V.) prior to listing.

High-value products addressing significant unmet medical need

- The P55 Application Cartridge addresses severe pneumonia infections and detects 21 pneumonia-causing pathogens and 19 clinically relevant resistance markers against antimicrobials.
- The i60 ITI Application Cartridge detects 61 microorganisms and 19 antibiotic resistance markers relevant for eight different clinical indications: prosthetic joint and other implant infections, diabetic foot ulcers, surgical site infections, catheter-associated infections, deep skin and tissue infections, cardiology-related infections, and burn wounds.
- Curetis' pipeline of product candidates includes Application Cartridges for blood culture testing and intra-abdominal/gastrointestinal tract infections and a sepsis host response Application Cartridge

Focus on global commercial expansion

- Curetis' Unyvero Systems and Application Cartridges are commercialized in Europe and certain other markets that accept CE-marking (i.e. Kuwait, Qatar, Russia and United Arab Emirates).
- Curetis also intends to further expand internationally as seen by the recent signing of distribution agreements with Acumen for certain ASEAN markets (initially Indonesia, Malaysia, Singapore and Thailand) and Beijing CLEAR Biotech for Greater China (consisting of China, Taiwan and Hong Kong).
- In the U.S., Curetis is currently running a prospective multi-center clinical trial aimed at achieving FDA clearance and a subsequent market launch in 2017.

Strong management team and investor base

- Curetis' management team combines decades of operational and commercial experience in the MDx industry.
- Curetis is backed by renowned investors, including Aeris Capital, LSP Life Sciences Partners, Forbion, HBM Partners, BioMed Partners, Roche Venture Fund, QIAGEN, CD-Venture and KfW.

Further company highlights

- Curetis controls all key aspects of its value chain;
- manufactures all Application Cartridges in-house, with its highly automated cleanroom assembly line;
- believes that its Unyvero Platform has the potential for menu expansion into other areas, such as oncology, companion diagnostics, transplant medicine and veterinary applications.

"Timely and precise information about pathogens and resistance markers is key in combating life-threatening infections", said Oliver Schacht, PhD, CEO of Curetis. "We are providing doctors with relevant information so that they can make informed treatment decisions within hours. We believe that this leads to better patient outcomes, shorter hospital stays, and decreased hospital costs. In addition, adequate antibiotic therapy decisions help to combat the spread of antibiotic resistance, a significant and increasing problem throughout the world."

"Curetis has developed a strong pipeline of high-value products addressing a significant unmet medical need in the infectious diseases space," said Frank Mühlenbeck, PhD, Chairman of the Supervisory Board of Curetis. "With its product pipeline of highly multiplexed molecular diagnostics solutions, the company is well positioned in the fast growing molecular diagnostics market."

The Offering and Listing

The intended Offering is expected to consist of a primary offering of newly issued ordinary shares in the capital of Curetis N.V. (the “**Shares**”) through (i) a public offering to retail and institutional investors in Germany and (ii) a private placement to certain institutional and other eligible investors in various other jurisdictions.

Certain of Curetis’ current shareholders have indicated their intention to subscribe for Shares offered in the Offering for an aggregate amount of about €15 million.

Curetis intends to use the net proceeds of the Offering:

- to build a commercial marketing, sales and support presence in the US in order to directly commercialize the Unyvero System and Application Cartridges following anticipated FDA clearance;
- to accelerate the R&D pipeline of its Unyvero Application Cartridges for European, US and other markets, including clinical trials and regulatory approvals;
- for expanding and strengthening its European commercial presence in markets where it sells the Unyvero Platform directly to end customers;
- for manufacturing capacity expansion and general corporate purposes.

Curetis intends to have all Shares admitted to listing and trading on Euronext in Amsterdam, a regulated market of Euronext Amsterdam N.V., as well as on Euronext in Brussels, a regulated market of Euronext Brussels N.V./S.A. The Offering and listing, and their timing, are subject to market and other conditions.

RBC Capital Markets is acting as Sole Global Coordinator for the Offering and RBC Capital Markets and Bank Degroof Petercam N.V./S.A. together are acting as Joint Bookrunners for the Offering. ICF Bank AG is acting as Joint Lead Manager for the Offering.

For further information, please visit www.unyvero.com.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over EUR 63.5 million (>US\$ 70 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cembra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

For further information, please visit www.curetis.com.

Contact

Curetis AG

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@curetis.com

www.curetis.com - www.unyvero.com

Media & Investor Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

Important legal information

These materials are for informational purposes only and are not intended to constitute, and should not be construed as, an offer to sell or subscribe for, or the announcement of a forthcoming offer to sell or subscribe for, or a solicitation of any offer to buy or subscribe for, or the announcement of a forthcoming solicitation of any offer to buy or subscribe for, ordinary Shares in the share capital of Curetis N.V. (the "**Company**") in the United States, Australia, Canada, Japan, South Africa or in any other jurisdiction to whom or in which such offer or solicitation is unlawful and the distribution of this communication in jurisdictions may be similarly restricted. Persons into whose possession this communication comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the security laws of any such jurisdiction.

The Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") and may not be offered or sold within the United States absent registration or an exemption from the registration requirements under the Securities Act. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the United States. The securities referred to herein may not be offered or sold in Australia, Canada, Japan, South Africa or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or South Africa.

The Company has not authorised any offer to the public of Shares in any Member State of the European Economic Area, except in the Federal Republic of Germany and the Netherlands. With respect to any Member State of the European Economic Area which has implemented the Prospectus Directive other than the Netherlands and Germany (each a "**Relevant Member State**"), no action has been undertaken or will be undertaken to make an offer to the public of Shares requiring publication of a prospectus in any Relevant Member State. As a result, the Shares may only be offered in Relevant Member States:

- (i) to any legal entity which is a "qualified investor" as defined in the Prospectus Directive; or
- (ii) in any other circumstances falling within Article 3(2) of the Prospectus Directive.

For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the Shares to be offered so as to enable the investor to decide to exercise, purchase or subscribe for the Shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "**Prospectus Directive**" means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

In the United Kingdom, this document and any other materials in relation to the Shares is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "**qualified investors**" (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having

professional experience in matters relating to investments who fall within the definition of "**investment professionals**" in Article 19(5) of the Financial Services and Markets Act 2000 ("**Financial Promotion**") Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "**relevant persons**"). This communication

is directed only at relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. No action has been taken by the Company that would permit an offer of Shares or the possession or distribution of these materials or any other offering or publicity material relating to such Shares in any jurisdiction, except for the Republic of Germany and the Netherlands, where action for that purpose is required.

This announcement is not an advertisement within the meaning of the Prospectus Directive and does not constitute a prospectus. The offer to acquire Shares will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding the Shares should exclusively be made on the basis of the prospectus. When made available, copies of the prospectus may be obtained at no cost from the Company and through the website of the Company.

This document may contain forward-looking statements. These statements are based on the current views, expectations and assumptions of the management of the Company and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. You can identify forward-looking statements by terms such as "believe", "anticipate", "expect", "estimate", "may", "could", "should", "would", "will", "intend", "plan", the negative of such terms or other similar expressions. Actual results, performance or events may differ materially from those described in such statements due to, among other things, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations and competition from other companies, changes in international and national laws and regulations, rapid technological and market change in the industries the Company operates in, as well as many other risks specifically related to the Company and its operations.. The Company does not assume any obligations to update any forward-looking statements.

Neither these materials nor any copy of it may be taken or transmitted, directly or indirectly, into the United States, Australia, Canada, Japan or South Africa. These materials do not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefore. The offer and the distribution of these materials and other information in connection with the listing and offer in certain jurisdictions may be restricted by law.